A large burden of undiagnosed hepatitis virus causes remains globally. Despite the 257 million people living with chronic hepatitis B virus infection, and 71 million with chronic viraemic HCV infection, most people with hepatitis remain unaware of their infection. When a patient progresses towards chronic conditions, there is a 25-40% chance (Hep C only) of liver cirrhosis and a 60% chance (Hep C only) of hepatocellular carcinoma (HCC).

HCC is the 6th most common cancer in the world and the 3rd leading cause of death from cancer. Two-thirds of these deaths are caused by hepatitis and HCC related to Hepatitic C infection is the fastest rising cause of cancer-related deaths.

The path towards hepatitis elimination depends on key factors of detection, diagnosis and linkage to care. Success of elimination will require introduction of novel serum biomarkers and fast innovative technologies to improve patient care pathways.

Steps Ahead In the Fight Against Viral Hepatitis
Click here to learn more

Solutions

products_default

M2BPGi – Novel serum biomarker for assessing Liver Fibrosis

Read more

M2BPGi – Novel serum biomarker for assessing Liver Fibrosis

Read more
products_default

Viral Hepatitis – Innovation in Hepatitis C Testing

Read more

Viral Hepatitis – Innovation in Hepatitis C Testing

Read more

Applications

products_default

Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients

Read more

Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients

Read more
Jekarl, Choi, Lee, Kwon, Lee, Yu, … Yoon. (2018). Annals of Laboratory Medicine, 38(4), 348–354
products_default

Diagnostic performance of Mac‐2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups.

Read more

Diagnostic performance of Mac‐2 binding protein glycosylation isomer (M2BPGi) in screening liver fibrosis in health checkups.

Read more
Nah, Eun‐Hee, et al. Journal of Clinical Laboratory Analysis (2020).
products_default

Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis

Read more

Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis

Read more
Shirabe et al. (2018). Journal of Gastroenterology, 1–8.
products_default

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection

Read more

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection

Read more
Mak, Lung-Yi, Danny Ka-Ho Wong, Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, and Man-Fung Yuen. Clinical and translational gastroenterology. 2018 Jun;9(6)
products_default

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population

Read more

Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population

Read more
Kim, Mimi, et al. Journal of Clinical Medicine 9.4 (2020): 1119
products_default

Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population.

Read more

Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population.

Read more
Pham TTT, Ho DT, Nguyen T. World J Hepatol 2020; 12(5): 220-229
products_default

Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non‐alcoholic fatty liver disease

Read more

Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non‐alcoholic fatty liver disease

Read more
Ogawa, Honda, Kessoku, Tomeno, & Imajo. (2018). Journal of Hepatology